Fatal gene-editing trial in China prompts concerns over regulatory tightening

The death of a pediatric patient in an experimental gene-editing trial has triggered calls for stricter oversight of clinical research in China. Industry participants fear this incident may lead to a reversal of the regulatory flexibility that has historically accelerated the nation's biotechnology sector, potentially hindering future innovation.